Tff Pharmaceuticals Inc (TFFP) Stock Records -29.77% Quarterly Movement

The stock of Tff Pharmaceuticals Inc (TFFP) has seen a -33.38% decrease in the past week, with a -26.94% drop in the past month, and a -29.77% decrease in the past quarter. The volatility ratio for the week is 21.57%, and the volatility levels for the past 30 days are at 17.89% for TFFP. The simple moving average for the past 20 days is -36.03% for TFFP’s stock, with a -39.30% simple moving average for the past 200 days.

Is It Worth Investing in Tff Pharmaceuticals Inc (NASDAQ: TFFP) Right Now?

Company’s 36-month beta value is 1.28.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for TFFP is 2.52M, and currently, short sellers hold a 1.84% ratio of that floaft. The average trading volume of TFFP on April 03, 2024 was 26.06K shares.

TFFP) stock’s latest price update

Tff Pharmaceuticals Inc (NASDAQ: TFFP) has experienced a decline in its stock price by -23.09 compared to its previous closing price of 6.41. However, the company has seen a fall of -33.38% in its stock price over the last five trading days. GlobeNewsWire reported 2024-01-24 that FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will present data from the Phase 2 trial of Voriconazole Inhalation Powder (TFF VORI) for the treatment of invasive pulmonary aspergillosis at the upcoming Advances Against Aspergillosis & Mucormycosis (AAAM) Conference, which will be held from January 25-27, 2024, in Milan, Italy. Data being presented at the AAAM Conference were first disclosed by the Company in December 2023.

Analysts’ Opinion of TFFP

Many brokerage firms have already submitted their reports for TFFP stocks, with H.C. Wainwright repeating the rating for TFFP by listing it as a “Buy.” The predicted price for TFFP in the upcoming period, according to H.C. Wainwright is $22 based on the research report published on May 19, 2022 of the previous year 2022.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see TFFP reach a price target of $31. The rating they have provided for TFFP stocks is “Buy” according to the report published on February 08th, 2021.

B. Riley Securities gave a rating of “Buy” to TFFP, setting the target price at $36 in the report published on December 07th of the previous year.

TFFP Trading at -26.27% from the 50-Day Moving Average

After a stumble in the market that brought TFFP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.80% of loss for the given period.

Volatility was left at 17.89%, however, over the last 30 days, the volatility rate increased by 21.57%, as shares sank -45.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.20% lower at present.

During the last 5 trading sessions, TFFP fell by -33.38%, which changed the moving average for the period of 200-days by -56.18% in comparison to the 20-day moving average, which settled at $7.50. In addition, Tff Pharmaceuticals Inc saw -29.77% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TFFP starting from CARLSON CAPITAL L P, who sale 1,000 shares at the price of $0.39 back on Aug 16 ’23. After this action, CARLSON CAPITAL L P now owns 5,064,000 shares of Tff Pharmaceuticals Inc, valued at $392 using the latest closing price.

Weisman Harlan F, the President and CEO of Tff Pharmaceuticals Inc, purchase 600,000 shares at $0.25 during a trade that took place back on Aug 15 ’23, which means that Weisman Harlan F is holding 814,615 shares at $150,000 based on the most recent closing price.

Stock Fundamentals for TFFP

The total capital return value is set at -2.29. Equity return is now at value -130.94, with -117.54 for asset returns.

Based on Tff Pharmaceuticals Inc (TFFP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -192.05. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 139.08.

Currently, EBITDA for the company is -22.13 million with net debt to EBITDA at 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.13.

Conclusion

In a nutshell, Tff Pharmaceuticals Inc (TFFP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts